nach oben

Current Urology Reports

Erschienen in:

01.01.2021 | NEW IMAGING TECHNIQUES (S Rais-Bahrami and K Porter, Section Editors)

From Diagnosis to Therapy—PET Imaging for Pheochromocytomas and Paragangliomas

verfasst von: Hiren V. Patel, Arnav Srivastava, Murray D. Becker, Toni Beninato, Amanda M. Laird, Eric A. Singer

Erschienen in: Current Urology Reports | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Pheochromocytoma and paraganglioma (PPGLs) are neuroendocrine tumors with diverse clinical presentations. PPGLs can be sporadic but often are associated with various syndromes, which can have variable clinical presentations. A thorough workup is therefore critical for staging, treatment, and follow-up. Imaging is an essential part of the workup and diagnosis of PPGLs.

Recent Findings

Improvements in cross-sectional imaging with radionuclides have increased specificity and sensitivity for identifying and treating PPGLs. Furthermore, a variety of targets on PPGLs has allowed for optimal imaging with radionuclides that can be used for staging and treatment. Currently, radionuclides are being evaluated for staging and treatment of PPGLs.

Summary

Developing novel radionuclides that can identify disease sites and target them simultaneously provides a potential for improving survival and outcomes in patients with PPGLs. Given the clinical diversity among PPGLs, expanding the therapeutic arsenal against locally advanced or metastatic PPGLs can allow clinicians to evaluate and treat PPGLs thoroughly.

Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–42. https://doi.org/10.1210/jc.2014-1498.CrossRefPubMed

Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–6.CrossRefPubMed

Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, et al. Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma. Eur J Endocrinol. 2009;161(2):355–61. https://doi.org/10.1530/EJE-09-0384.CrossRefPubMed

Wen J, Li HZ, Ji ZG, Mao QZ, Shi BB, Yan WG. A decade of clinical experience with extra-adrenal paragangliomas of retroperitoneum: report of 67 cases and a literature review. Urol Ann. 2010;2(1):12–6. https://doi.org/10.4103/0974-7796.62919.CrossRefPubMedPubMedCentral

Somasundar P, Krouse R, Hostetter R, Vaughan R, Covey T. Paragangliomas--a decade of clinical experience. J Surg Oncol. 2000;74(4):286–90. https://doi.org/10.1002/1096-9098(200008)74:4<286::aid-jso9>3.0.co;2-c.CrossRefPubMed

6.•

Neumann HPH, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552–65. https://doi.org/10.1056/NEJMra1806651A comprehensive review of PPGLs and genetic basis for these tumors.CrossRefPubMed

Plouin PF, Amar L, Dekkers OM, Fassnacht M, Gimenez-Roqueplo AP, Lenders JW, et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016;174(5):G1–G10. https://doi.org/10.1530/EJE-16-0033.CrossRefPubMed

Kiernan CM, Solorzano CC. Pheochromocytoma and paraganglioma: diagnosis, genetics, and treatment. Surg Oncol Clin N Am. 2016;25(1):119–38. https://doi.org/10.1016/j.soc.2015.08.006.CrossRefPubMed

Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res. 2017;23(12):e68–75. https://doi.org/10.1158/1078-0432.CCR-17-0547.CrossRefPubMed

10.

Benn DE, Robinson BG, Clifton-Bligh RJ. 15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer. 2015;22(4):T91–103. https://doi.org/10.1530/ERC-15-0268.CrossRefPubMedPubMedCentral

11.

Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346(19):1459–66. https://doi.org/10.1056/NEJMoa020152.CrossRefPubMed

12.

Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39(3):178–83.CrossRefPubMedPubMedCentral

13.

Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91(11):4505–9. https://doi.org/10.1210/jc.2006-0423.CrossRefPubMed

14.

Benn DE, Robinson BG. Genetic basis of phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2006;20(3):435–50. https://doi.org/10.1016/j.beem.2006.07.005.CrossRefPubMed

15.

Ricketts CJ, Forman JR, Rattenberry E, Bradshaw N, Lalloo F, Izatt L, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat. 2010;31(1):41–51. https://doi.org/10.1002/humu.21136.CrossRefPubMed

16.

Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab. 1998;83(6):2175–85. https://doi.org/10.1210/jcem.83.6.4870.CrossRefPubMed

17.

Manu P, Runge LA. Biochemical screening for pheochromocytoma. Superiority of urinary metanephrines measurements. Am J Epidemiol. 1984;120(5):788–90.CrossRefPubMed

18.

Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995;123(2):101–9.CrossRefPubMed

19.

Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340(24):1872–9. https://doi.org/10.1056/NEJM199906173402404.CrossRefPubMed

20.

Lenders JW, Willemsen JJ, Eisenhofer G, Ross HA, Pacak K, Timmers HJ, et al. Is supine rest necessary before blood sampling for plasma metanephrines? Clin Chem. 2007;53(2):352–4. https://doi.org/10.1373/clinchem.2006.076489.CrossRefPubMed

21.

Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83. https://doi.org/10.1097/MPA.0b013e3181ebb4f0.CrossRefPubMedPubMedCentral

22.

Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003;88(6):2656–66. https://doi.org/10.1210/jc.2002-030005.CrossRefPubMed

23.

Darr R, Lenders JW, Stange K, Kindel B, Hofbauer LC, Bornstein SR, et al. Diagnosis of pheochromocytoma and paraganglioma: the clonidine suppression test in patients with borderline elevations of plasma free normetanephrine. Dtsch Med Wochenschr. 2013;138(3):76–81. https://doi.org/10.1055/s-0032-1327395.CrossRefPubMed

24.

Lumachi F, Tregnaghi A, Zucchetta P, Cristina Marzola M, Cecchin D, Grassetto G, et al. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study. Nucl Med Commun. 2006;27(7):583–7.CrossRefPubMed

25.

Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med. 1993;34(2):173–9.PubMed

26.

Baez JC, Jagannathan JP, Krajewski K, O’Regan K, Zukotynski K, Kulke M, et al. Pheochromocytoma and paraganglioma: imaging characteristics. Cancer Imaging. 2012;12:153–62. https://doi.org/10.1102/1470-7330.2012.0016.CrossRefPubMedPubMedCentral

27.

Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. AJR Am J Roentgenol. 2013;200(2):370–8. https://doi.org/10.2214/AJR.12.9126.CrossRefPubMed

28.

Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9):1448–54. https://doi.org/10.2967/jnumed.108.058701.CrossRefPubMed

29.

Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol. 1999;6(3):119–24.CrossRefPubMed

30.

Mozley PD, Kim CK, Mohsin J, Jatlow A, Gosfield E 3rd, Alavi A. The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma. J Nucl Med. 1994;35(7):1138–44.PubMed

31.

van der Horst-Schrivers AN, Kerstens MN, Wolffenbuttel BH. Preoperative pharmacological management of phaeochromocytoma. Neth J Med. 2006;64(8):290–5.PubMed

32.

Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37(12):2436–46. https://doi.org/10.1007/s00259-010-1545-7.CrossRefPubMed

33.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700–8. https://doi.org/10.1093/jnci/djs188.CrossRefPubMedPubMedCentral

34.

Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262–9. https://doi.org/10.1200/JCO.2006.09.6297.CrossRefPubMed

35.

Garrigue P, Bodin-Hullin A, Balasse L, Fernandez S, Essamet W, Dignat-George F, et al. The evolving role of succinate in tumor metabolism: an (18)F-FDG-based study. J Nucl Med. 2017;58(11):1749–55. https://doi.org/10.2967/jnumed.117.192674.CrossRefPubMedPubMedCentral

36.

Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, et al. Biodistribution and dosimetry of (18)F-meta-fluorobenzylguanidine: a first-in-human PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59(1):147–53. https://doi.org/10.2967/jnumed.117.193169.CrossRefPubMedPubMedCentral

37.

Fiebrich HB, Brouwers AH, Kerstens MN, Pijl ME, Kema IP, de Jong JR, et al. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab. 2009;94(10):3922–30. https://doi.org/10.1210/jc.2009-1054.CrossRefPubMed

38.

Fonte JS, Robles JF, Chen CC, Reynolds J, Whatley M, Ling A, et al. False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer. 2012;19(1):83–93. https://doi.org/10.1530/ERC-11-0243.CrossRefPubMedPubMedCentral

39.

Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results. Radiology. 2002;222(2):507–12. https://doi.org/10.1148/radiol.2222010622.CrossRefPubMed

40.

Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613–9. https://doi.org/10.2967/jnumed.108.052373.CrossRefPubMed

41.

Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757–67. https://doi.org/10.1210/jc.2009-1248.CrossRefPubMedPubMedCentral

42.

Timmers HJ, Eisenhofer G, Carrasquillo JA, Chen CC, Whatley M, Ling A, et al. Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol. 2009;71(1):11–7. https://doi.org/10.1111/j.1365-2265.2008.03496.x.CrossRef

43.

Vyakaranam AR, Crona J, Norlén O, Hellman P, Sundin A. (11)C-hydroxy-ephedrine-PET/CT in the diagnosis of pheochromocytoma and paraganglioma. Cancers (Basel). 2019;11(6). https://doi.org/10.3390/cancers11060847.

44.

Ivanidze J, Roytman M, Sasson A, Skafida M, Fahey TJ 3rd, Osborne JR, et al. Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging. 2019;56:146–54. https://doi.org/10.1016/j.clinimag.2019.04.006.CrossRefPubMed

45.

Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500–16. https://doi.org/10.1148/rg.352140164.CrossRefPubMed

46.••

Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, et al. (68)Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with (18)F-DOPA PET/CT. Rev Esp Med Nucl Imagen Mol. 2019;38(2):94–9. https://doi.org/10.1016/j.remn.2018.09.004Shows superiority of ⁶⁸Ga-DOTATOC in detecting metastatic PPGLs compared to ¹⁸F-DOPA.CrossRefPubMed

47.

Naji M, A AL-N, et al. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S61–7. https://doi.org/10.1007/s00259-011-1990-y.CrossRefPubMed

48.

Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769–75. https://doi.org/10.1007/s11307-010-0396-8.CrossRefPubMed

49.

Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, et al. Accuracy of 68Ga DOTANOC PET/CT imaging in patients with multiple endocrine Neoplasia syndromes. Clin Nucl Med. 2015;40(7):e351–6. https://doi.org/10.1097/RLU.0000000000000775.CrossRefPubMed

50.

Hamidi O. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. Curr Opin Endocrinol Diabetes Obes. 2019;26(3):146–54. https://doi.org/10.1097/MED.0000000000000476.CrossRefPubMed

51.

Archier A, Varoquaux A, Garrigue P, Montava M, Guerin C, Gabriel S, et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43(7):1248–57. https://doi.org/10.1007/s00259-015-3268-2.CrossRefPubMed

52.

Hofman MS, Hicks RJ. Moving beyond “Lumpology”: PET/CT imaging of pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21(17):3815–7. https://doi.org/10.1158/1078-0432.CCR-15-1073.CrossRefPubMed

53.

Janssen I, Blanchet EM, Adams K, Chen CC, Millo CM, Herscovitch P, et al. Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin Cancer Res. 2015;21(17):3888–95. https://doi.org/10.1158/1078-0432.CCR-14-2751.CrossRefPubMedPubMedCentral

54.

Janssen I, Chen CC, Taieb D, Patronas NJ, Millo CM, Adams KT, et al. 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med. 2016;57(2):186–91. https://doi.org/10.2967/jnumed.115.161018.CrossRefPubMed

55.

Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, et al. A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging. 2013;40(12):1800–8. https://doi.org/10.1007/s00259-013-2548-y.CrossRefPubMed

56.

Tan TH, Hussein Z, Saad FF, Shuaib IL. Diagnostic performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma. Nucl Med Mol Imaging. 2015;49(2):143–51. https://doi.org/10.1007/s13139-015-0331-7.CrossRefPubMedPubMedCentral

57.

Taieb D, Pacak K. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell Tissue Res. 2018;372(2):393–401. https://doi.org/10.1007/s00441-018-2791-4.CrossRefPubMedPubMedCentral

58.

Strajina V, Dy BM, Farley DR, Richards ML, McKenzie TJ, Bible KC, et al. Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series. Ann Surg Oncol. 2017;24(6):1546–50. https://doi.org/10.1245/s10434-016-5739-5.CrossRefPubMed

59.

Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, et al. Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma. Ann Surg. 2017;268:172–8. https://doi.org/10.1097/SLA.0000000000002195.CrossRef

60.

Administration UFaD. FDA approves iobenguane I 131 for rare adrenal gland tumors. 2018. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-iobenguane-i-131-rare-adrenal-gland-tumors. 2020.

61.••

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35. https://doi.org/10.1056/NEJMoa1607427Demonstrates efficacy of ¹⁷⁷Lu-DOTATATE in midgut neuroendocrine tumors.CrossRefPubMedPubMedCentral

62.

Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334–40.PubMed

63.

Frilling A, Weber F, Saner F, Bockisch A, Hofmann M, Mueller-Brand J, et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery. 2006;140(6):968–76; discussion 76-7. https://doi.org/10.1016/j.surg.2006.07.030.CrossRefPubMed

64.

van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599–606.PubMed

65.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–23. https://doi.org/10.1200/JCO.2010.33.7873.CrossRefPubMed

66.

Zovato S, Kumanova A, Dematte S, Sansovini M, Bodei L, Di Sarra D, et al. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44(5):411–4. https://doi.org/10.1055/s-0032-1311637.CrossRefPubMed

Titel: From Diagnosis to Therapy—PET Imaging for Pheochromocytomas and Paragangliomas
verfasst von: Hiren V. Patel
Arnav Srivastava
Murray D. Becker
Toni Beninato
Amanda M. Laird
Eric A. Singer
Publikationsdatum: 01.01.2021
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 1/2021
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-020-01021-x

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

From Diagnosis to Therapy—PET Imaging for Pheochromocytomas and Paragangliomas

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia

Dual-Energy CT for Urinary Stone Evaluation

MR-Guided High-Intensity Directional Ultrasound Ablation of Prostate Cancer

What Is New with Rezūm Water Vapor Thermal Therapy for LUTS/BPH?

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie